Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...

Descripción completa

Detalles Bibliográficos

Autores principales:	Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2023-07-01
Colección:	Clinical and Translational Radiation Oncology
Materias:	Lung cancer Immunotherapy Radiotherapy Durvalumab Toxicity Prognosis
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S240563082300068X
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!